By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...

If you're an investor looking for stocks that can make dramatic gains in a short amount of time, you may have noticed a small-cap biopharmaceutical company called Instil Bio (NASDAQ: TIL) has been ...

Instil Bio said its subsidiary has discontinued clinical development of AXN-2510 and terminated its collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) for AXN-2510 and AXN-27M.

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a ...

Shares of small biotech Instil Bio TIL have surged more than six times in market value in the past week. The upside came after rival Summit Therapeutics SMMT reported encouraging data from a ...

ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC ...

DALLAS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of ...

Instil Bio, Inc. (NASDAQ: TIL) stock is trading lower on Tuesday. Axion Bio Inc., a wholly-owned subsidiary of Instil, decided to discontinue clinical development of AXN-2510. AXN-2510, Instil’s lead ...

DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue ...

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (TIL) (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code ...